Zevra therapeutics to present data demonstrating relevance of swallow domain in niemann-pick disease type c clinical severity scale at 53rd child neurology society annual meeting

Data show that the npccss swallow score reflects the patient's level of dysfunction study indicates that a change in score reflects actual improvement or worsening in a patient's swallowing function celebration, fla., nov. 11, 2024 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced that elizabeth berry-kravis, m.d.
ZVRA Ratings Summary
ZVRA Quant Ranking